Patent application number | Description | Published |
20090069287 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS - The invention relates to substituted azacycloalkaπe compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditions in which inhibition of beta-secretase is indicated. | 03-12-2009 |
20110046160 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. | 02-24-2011 |
20130053373 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, | 02-28-2013 |
20130150376 | Novel Sultam Compounds - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. | 06-13-2013 |
20130296308 | Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, | 11-07-2013 |
20140163015 | HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS - The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure | 06-12-2014 |
20140323474 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure | 10-30-2014 |
20140364426 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, | 12-11-2014 |
20150087637 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, | 03-26-2015 |
Patent application number | Description | Published |
20130167392 | SELF IDENTIFYING TEMPLATE GAGE PROBING SYSTEM - A component inspection system comprises a sensor apparatus and a template having a component side and an opposing inspection side. The inspection side includes a plurality of inspection bosses projecting therefrom, each of the plurality of inspection bosses having a first coupling and a sensor aperture. Each aperture is disposed axially through each respective boss to the component side of the template. The sensor apparatus includes a receptacle for retaining a sensor. The receptacle has a second coupling configured to individually engage with each of the plurality of first couplings for removably securing the sensor apparatus to a respective at least one of the plurality of inspection bosses. | 07-04-2013 |
20140170012 | Additive manufacturing using partially sintered layers - The invention relates to an additive manufacturing apparatus and method. According to the invention, an additive manufacturing apparatus includes a material supply system. The material supply system delivers layers of partially sintered pulverant material to an additive manufacturing device. | 06-19-2014 |
20140186098 | WORK PIECE HAVING SELF-SUPPORTING GUSSET AND METHOD RELATED THERETO - A powder-derived, non-finished work piece includes a first body section that has a wall that spans in a vertical direction. The wall has a relatively thin thickness with respect to a length and a width of the wall. A second body section is arranged next to, but spaced apart from, the first body section. A gusset connects the first body section and the second body section. The gusset extends obliquely from the wall of the first body section with respect to the vertical direction such that the gusset is self-supporting. The first body section has a geometry that corresponds to an end-use component exclusive of the gusset. | 07-03-2014 |
20140186205 | METHOD AND APPARATUS FOR RECONDITIONING OXIDIZED POWDER - A metal powder reconditioning apparatus and method recondition contaminated residual powder from an additive manufacturing device. The apparatus and method include a reducing chamber that receives contaminated residual powder resulting from an additive manufacturing process and remove oxygen from the contaminated residual powder to produce reconditioned powder. The reconditioned powder may be reused in the additive manufacturing process, or may be stored in a non-oxidizing atmosphere for later reuse. | 07-03-2014 |
20140271221 | USAGE OF A WITNESS MARK TO DISTINGUISH SUPPORT STRUCTURE FROM PART - A component includes a support structure made with an additive manufacturing process with a first end and a second end, and an object made with an additive manufacturing process with a first end and a second end, where the first end of the object is attached to the second end of the support structure. A cross-sectional area of the first end of the object is larger than a cross-sectional area of the second end of the support structure. A method of making an object, the method includes manufacturing a support structure with an additive manufacturing process. An object is manufactured on top of and connected to the support structure with an additive manufacturing process, wherein there is a witness mark created between the support structure and the object. The witness mark is identified. The object is separated from the support structure along the witness mark. | 09-18-2014 |
Patent application number | Description | Published |
20110054523 | System And Method For Creating End Effector - A suture including a knotted end effector is provided. The suture includes a body portion defining a longitudinal axis and an end effector integrally formed from the body portion, the end effector having first and second sections, each section including at least two throws, the at least two throws of the second section passing through the at least two throws of the first section. The number of throws in the first section may be the same or different from the number of throws in the second section. | 03-03-2011 |
20110079341 | Welded Knot End Effector - An apparatus for forming an end effector includes a welding device having a welder positioned adjacent to a base, and a die coupled to one end of the welder. The base and the welder are movable relative to each other. The welder, base or die includes a source of heat that is applied to a portion of the suture disposed between the welder and the base. | 04-07-2011 |
20130020012 | Welded Knot End Effector - An apparatus for forming an end effector includes a welding device having a welder positioned adjacent to a base, and a die coupled to one end of the welder. The base and the welder are movable relative to each other. The welder, base or die includes a source of heat that is applied to a portion of the suture disposed between the welder and the base. | 01-24-2013 |
Patent application number | Description | Published |
20130280640 | COMPACT FUEL CELL SYSTEM - An example fuel cell system includes a fuel cell power plant and a tank providing a volume that is configured to hold a fuel cell fluid. The fuel cell power plant is at least partially disposed within the volume. | 10-24-2013 |
20130323623 | FUEL CELL FLUID CHANNELS - An example fuel cell assembly includes a plate having channels configured to facilitate movement of a fuel cell fluid near an area of active flow of fuel cell. The channels include portions having a varying depth that extend laterally outside of the area of active flow. | 12-05-2013 |
20140147770 | LOW PLATINUM LOAD ELECTRODE - An electrode for an electrochemical cell includes platinum catalysts, carbon support particles and an ionomer. The carbon support particles support the platinum catalysts, and the ionomer connects the platinum catalysts. The electrode has a platinum less than about 0.2 mg/cm | 05-29-2014 |
20140349201 | FUEL CELL ASSEMBLY AND METHOD OF CONTROL - An exemplary method includes of operating a fuel cell at a first power output level that includes a plurality of operation parameters. Each operation parameter has a value to satisfy a first power demand. A change between the first power demand and a second power demand is determined. At least a first one of the operation parameters is maintained at a value corresponding to the first power output level or at an intermediate value while at least a second one of the operation parameters is changed to a value corresponding to a second power output level to satisfy the second power demand. The first operation parameter is delayed from changing to a value corresponding to the second power output level until a predetermined criterion is met. | 11-27-2014 |
20150030964 | METHOD OF MAKING A FUEL CELL COMPONENT HAVING AN INTERDIGITATED FLOW FIELD CONFIGURATION - According to an illustrative embodiment, a method of making a fuel cell component includes removing material from a first plurality of locations along at least one surface on a plate to simultaneously establish a plurality of first channels on the surface. Each first channel has a length between a first end near a first edge of the surface and a second end spaced from a second, opposite edge of the surface. Material is also removed from a second plurality of locations along the surface to simultaneously establish a plurality of second channels on the surface. Each second channel has a length beginning at a first end spaced from the first edge and a second end near the second edge. Material is also removed from the surface near the first ends of at least some of the first channels to simultaneously establish an inlet portion for directing a fluid into the corresponding first channels. | 01-29-2015 |
20150079487 | FUEL CELL WITH IMPURITY FILTERING - A system has a fuel cell with an anode, a membrane, and a cathode. A source of fuel passes along the anode and a source of an oxygen containing gas passes along the cathode. A downstream line captures fuel downstream of the anode and a separator separates impurities from the fuel on the downstream line, and recirculates fuel downstream of the separator for passage across the anode. A method of mixing air with an oxygen concentrated gas is also disclosed. | 03-19-2015 |
Patent application number | Description | Published |
20080299096 | MODIFIED NUCLEOTIDE SEQUENCE ENCODING GLUCAGON-LIKE PEPTIDE-1 (GLP-1), NUCLEIC ACID CONSTRUCT COMPRISING SAME FOR PRODUCTION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1), HUMAN CELLS COMPRISING SAID CONSTRUCT AND INSULIN-PRODUCING CONSTRUCTS, AND METHODS OF USE THEREOF - An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner. | 12-04-2008 |
20110076257 | Modified Nucleotide Sequence Encoding Glucagon-Like Peptide-1 (GLP-1), Nucleic Acid Construct Comprising Same for Production of Glucagon-Like Peptide-1 (GLP-1), Human Cells Comprising Said Construct and Insulin-Producing Constructs, and Method of Use Thereof - An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner. | 03-31-2011 |